Dupixent (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old. 68% of children on a higher dose of Dupixent achieved histological disease remission at week 16.
🌍 Sanofi (SNY) - Form 6-K Filing
Filing Date: 2022-10-17
Accepted: 2022-10-17 13:35:53
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: